InvestSMART

Platformo Ltd (ASX:PFM)

ALERT: Price-sensitive ASX Announcement for PFM
Current share price for PFM : $0.026 -0.007 (-21.21%)+
Announcement
Release
31 Oct 2025 9:27AM
Price at Release
$0.033
Full Release
download
Summary
Platformo Ltd's quarterly activities report for September 2025 details the financial and operational performance of its subsidiary, Biztrak Business Solutions. The company experienced a decline in revenue by 30% due to deferred demand following revised e-invoicing compliance timelines in Malaysia. Cash usage surged due to payments for ASX listing and audit fees, although the company closed the quarter with AUD 1,158k in cash. Management undertook cost control measures to address reduced cash flow, while strategic participation in industry events aimed to bolster market presence. The report emphasized ongoing efforts to manage financial challenges and seek shareholder value addition.
Key Points
  • Platformo Ltd, trading as ASX: PFM, focuses on Biztrak Business Solutions, a software company operating in Malaysia and other Asian countries.
  • The quarterly report highlighted the impact of the revised e-invoicing compliance timelines in Malaysia, which resulted in deferred demand from smaller Biztrak clients.
  • Biztrak's revenue for the September 2025 quarter fell by 30% compared to the previous year due to changes in the compliance timeline and decreased demand for e-invoicing services.
  • The company reported a cash balance of AUD 1,158k at the end of September 2025.
  • The report noted an increased cash usage due to one-time payments for ASX listing and audit fees.
  • Management has implemented cost control measures to mitigate the impact of reduced cash flow and revenue from Biztrak.
  • Biztrak participated in strategic industry events to enhance market presence, including the SAGA Government Agency Conference and the Malaysian International Trade Fair.
  • Net cash outflows increased to AUD 204k during the quarter due to weakened cash collections and other financial commitments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.